Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Ovarian Neoplasms

Free Subscription Articles published in Oncogene Retrieve available abstracts of 56 articles: HTML format

Single Articles

May 2026
1. LI Y, Chen Z, Diao Y, Gao Q, et al
   SNRPD2-CPSF7-UBE2K axis drives ovarian cancer progression via alternative splicing-polyadenylation crosstalk.
   Oncogene. 2026 May 7. doi: 10.1038/s41388-026-03812.
   PubMed     Abstract available
   
   
   April 2026
2. WEI Y, Chen Z, Li Y, Song K, et al
   Correction: The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
   Oncogene. 2026 Apr 23. doi: 10.1038/s41388-026-03810.
   PubMed    
   
   
   
3. LOBERMEYER A, Schollhorn JS, Rademacher PN, Wankner MC, et al
   Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.
   Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03747.
   PubMed     Abstract available
   
   
   
4. PU Y, Chen Z, Gao Q, Liu Y, et al
   Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer.
   Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03764.
   PubMed     Abstract available
   
   
   March 2026
5. PEI X, Wang F, Liu X, Lei Y, et al
   Core fucosylation of NCEH1 by FUT8 promotes progression of high-grade serous ovarian cancer by driving tumor-associated macrophage M2 polarization.
   Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03703.
   PubMed     Abstract available
   
   
   
6. WEBB JD, Buensuceso A, Tomas EJ, Borrelli MJ, et al
   ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.
   Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03702.
   PubMed     Abstract available
   
   
   February 2026
7. CHENG G, Jiang W, Li Z, Ma Y, et al
   TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.
   Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03692.
   PubMed     Abstract available
   
   
   
8. XU J, Shi G, Qin Z, Yin B, et al
   Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
   Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03693.
   PubMed     Abstract available
   
   
   
9. VISWANADHAPALLI S, Lee TK, Elmore S, Sharma G, et al
   Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.
   Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03689.
   PubMed     Abstract available
   
   
   January 2026
10. SUN J, Cai X, Yung MMH, Zhou W, et al
    Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
    PubMed    
    
    
    December 2025
11. JI F, Yan K, Ding B, Zhu Y, et al
    Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
    Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
    PubMed     Abstract available
    
    
    
12. LI Q, Zhang S, Wang M, Yi Q, et al
    Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
    PubMed    
    
    
    November 2025
13. LIU S, He Y, Ning X, Xu W, et al
    SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
    Oncogene. 2025 Nov 28. doi: 10.1038/s41388-025-03584.
    PubMed     Abstract available
    
    
    October 2025
14. TANG S, Chen K, Zheng F, Fu Z, et al
    High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-kappaB1 pathway in epithelial ovarian cancer.
    Oncogene. 2025 Oct 22. doi: 10.1038/s41388-025-03609.
    PubMed     Abstract available
    
    
    
15. WU L, Wu C, He S, Chen Y, et al
    METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
    Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
    PubMed     Abstract available
    
    
    September 2025
16. HUANG L, Zhu M, Chen M, Ying F, et al
    LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
    PubMed     Abstract available
    
    
    August 2025
17. LI Q, Zhang S, Wang M, Yi Q, et al
    Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
    PubMed     Abstract available
    
    
    July 2025
18. SHEN C, Cao R, Zhou Q, Zhou T, et al
    LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
    Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
    PubMed     Abstract available
    
    
    May 2025
19. SONG C, Lin Y, Cai C, Tao K, et al
    LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
    Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
    PubMed     Abstract available
    
    
    
20. NARAYANA RVL, Gupta R
    Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
    PubMed     Abstract available
    
    
    April 2025
21. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
    Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
    PubMed     Abstract available
    
    
    
22. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed     Abstract available
    
    
    
23. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    PubMed     Abstract available
    
    
    March 2025
24. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    PubMed     Abstract available
    
    
    
25. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    PubMed     Abstract available
    
    
    
26. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    PubMed    
    
    
    February 2025
27. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    PubMed     Abstract available
    
    
    
28. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    PubMed     Abstract available
    
    
    December 2024
29. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    PubMed     Abstract available
    
    
    
30. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    PubMed     Abstract available
    
    
    October 2024
31. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    PubMed     Abstract available
    
    
    
32. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    PubMed     Abstract available
    
    
    
33. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    PubMed     Abstract available
    
    
    September 2024
34. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    PubMed     Abstract available
    
    
    
35. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    PubMed     Abstract available
    
    
    August 2024
36. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    PubMed     Abstract available
    
    
    June 2024
37. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    PubMed     Abstract available
    
    
    May 2024
38. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    PubMed     Abstract available
    
    
    April 2024
39. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed     Abstract available
    
    
    
40. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    PubMed     Abstract available
    
    
    
41. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    PubMed     Abstract available
    
    
    January 2024
42. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    PubMed     Abstract available
    
    
    
43. LIU H, Deng S, Yao X, Liu Y, et al
    Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
    Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
    PubMed     Abstract available
    
    
    
44. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    PubMed     Abstract available
    
    
    December 2023
45. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    PubMed     Abstract available
    
    
    November 2023
46. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    PubMed     Abstract available
    
    
    
47. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    PubMed     Abstract available
    
    
    October 2023
48. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    PubMed     Abstract available
    
    
    
49. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023;42:3047-3061.
    PubMed     Abstract available
    
    
    September 2023
50. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    PubMed     Abstract available
    
    
    August 2023
51. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    PubMed     Abstract available
    
    
    July 2023
52. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    PubMed     Abstract available
    
    
    June 2023
53. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    PubMed     Abstract available
    
    
    April 2023
54. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    PubMed     Abstract available
    
    
    March 2023
55. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    PubMed    
    
    
    
56. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum